| Tumor intrinsic PD-L1 promotes DNA Repair in distinct cancers and suppresses PARP inhibitor–induced synthetic lethality AVR Kornepati, JT Boyd, CE Murray, J Saifetiarova, B de la Peña Avalos, ... Cancer research 82 (11), 2156-2170, 2022 | 29 | 2022 |
| Reversing post-infectious epigenetic-mediated immune suppression Abhimanyu, CO Ontiveros, RS Guerra-Resendez, T Nishiguchi, M Ladki, ... Frontiers in immunology 12, 688132, 2021 | 20 | 2021 |
| Pharmacologic tumor PDL1 depletion with cefepime or ceftazidime promotes DNA damage and sensitivity to DNA-damaging agents C Murray, E Galvan, C Ontiveros, Y Deng, H Bai, AS Padron, ... International journal of molecular sciences 23 (9), 5129, 2022 | 6 | 2022 |
| Alternative splicing of the SUMO1/2/3 transcripts affects cellular SUMOylation and produces functionally distinct SUMO protein isoforms ML Acuña, A García-Morin, R Orozco-Sepúlveda, C Ontiveros, A Flores, ... Scientific reports 13 (1), 2309, 2023 | 2 | 2023 |
| Cutting Edge: Cytosolic Receptor AIM2 Is Induced by Peroxisome Proliferator-activated Receptor γ following Mycobacterium tuberculosis Infection of Human … E Arnett, J Wolff, CM Leopold Wager, J Simper, JL Badrak, CO Ontiveros, ... The Journal of Immunology 212 (5), 765-770, 2024 | 1 | 2024 |
| Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1 … H Bai, AS Padron, Y Deng, YJ Liao, CJ Murray, C Ontiveros, SJ Kari, ... Journal for Immunotherapy of Cancer 11 (2), 2023 | 1 | 2023 |
| Characterization of AIM2 expression in human macrophages during M. tuberculosis infection CO Ontiveros, E Arnett, LS Schlesinger The Journal of Immunology 202 (1_Supplement), 62.11-62.11, 2019 | 1 | 2019 |
| 1488 Melanoma cell-of-origin PDL1 promotes early tumor progression and distinct immune outcomes in a novel autochthonous NRAS-mutant melanoma model C Ontiveros, C Murray, H Bai, MJ Turk, T Curiel Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Considerations and Approaches for Cancer Immunotherapy in the Aging Host CO Ontiveros, CE Murray, G Crossland, TJ Curiel Cancer Immunology Research 11 (11), 1449-1461, 2023 | | 2023 |
| Pharmacologic tumor PDL1 depletion as a novel approach to overcome treatment resistance C Murray, H Bai, CO Ontiveros, P Blinkiewicz, E Galvan, Y Deng, ... The Journal of Immunology 210 (1_Supplement), 230.08-230.08, 2023 | | 2023 |
| Melanocyte PDL1 promotes early tumor progression in a novel autochthonous NRAS-mutant melanoma model CO Ontiveros, T Chen, C Murray, A Kornepati, Y Deng, P Blinkiewicz, ... The Journal of Immunology 210 (1_Supplement), 88.11-88.11, 2023 | | 2023 |
| 1428 Melanocyte-intrinsic PDL1 promotes tumorigenesis and progression in a novel autochthonous melanoma model C Ontiveros, Y Deng, A Kornepati, C Murray, MJ Turk, H Gupta, A Padron, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 501 Anti-PDL2 uses IL17-driven interferon-gamma to treat aged but not young cutaneous melanoma-bearing mice, and treats other tumors in an age-and TME-dependent manner M Garcia, Y Deng, C Murray, C Ontiveros, A Padron, S Skopelja-Gardner, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| 453 Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities C Murray, H Bai, A Kornepati, C Ontiveros, Y Deng, A Padron, E Galvan, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Alternative splicing of the SUMO transcripts contributes to the regulation of the cellular SUMOylation system and produces messages coding for protein isoforms functionally … ML Acuña, A García-Morin, R Orozco-Sepúlveda, C Ontiveros, A Flores, ... | | 2022 |
